| HOME >> BIOLOGY >> TECHNOLOGY |
Process to Explore Strategic Alternatives Ongoing
In February 2008, MiddleBrook announced that it engaged Morgan Stanley as its strategic advisor in the Company's ongoing strategic evaluation process. MiddleBrook is evaluating a full range of available strategic alternatives intended to further enhance shareholder value.
Strategic alternatives the Company may pursue could include, but are
not limited to, continued execution of the Company's operating plan, the
sale of some or all of the Company's assets, partnering or other
collaboration agreements, or a merger or other strategic transaction. There
can be no assurance that the exploration of strategic alternatives will
result in any agreements or transactions, or that, if completed, any
agreements or transactions will be successful or on attractive terms. The
Company does not intend to disclose developments with respect to this
process unless and until the evaluation of strategic alternatives has been
completed.
FINANCIAL DETAILS
-- Total revenue, resulting entirely from net Keflex product sales, was
$2.9 million in the fourth quarter of 2007, compared to revenue of $3.1
million in the prior quarter, and $1.2 million for the fourth quarter
of 2006. Revenue during the full year of 2007 was $10.5 million, up
from revenue of $4.8 million during the full year of 2006. Increased
product sales in 2007 were mainly attributable to the Company's Keflex
750 mg strength capsules which were launched during the second half of
2006.
-- Operating expenses. Research and development expenses, which primarily
consist of salaries, stock-based compensation, and related expenses for
<| SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |